Back to Search
Start Over
Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Aug 13; Vol. 12, pp. 701590. Date of Electronic Publication: 2021 Aug 13 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed. However, its effect on the offspring of patients with PCOS remains uncertain. This study investigated the impact of metformin treatment on the first- and second-generation female offspring born to letrozole-induced PCOS-IR rats. Forty-five female Wistar rats were implanted with continuous-release letrozole pellets or placebo and treated with metformin or vehicle control. Rats exposed to letrozole showed PCOS-like reproductive, endocrine, and metabolic phenotypes in contrast to the controls. Metformin significantly decreased the risk of body weight gain and increased INSR expression in F1 female offspring in PCOS-IR rats, contributing to the improvement in obesity, hyperinsulinemia, and IR. Decreased FSHR expression and increased LHCGR expression were observed in F1 female rats of the PCOS-IR and PCOS-IR+Metformin groups, suggesting that FSHR and LHCGR dysfunction might promote the development of PCOS. Nevertheless, we found no significant differences in INSR , FSHR , and LHCGR expression or other PCOS phenotypes in F2 female offspring of PCOS-IR rats. These findings indicated widespread reproductive, endocrine, and metabolic changes in the PCOS-IR rat model, but the PCOS phenotypes could not be stably inherited by the next generations. Metformin might have contributed to the improvement in obesity, hyperinsulinemia, and IR in F1 female offspring. The results of this study could be used as a theoretical basis in support of using metformin in the treatment of PCOS-IR patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Xie, Xiao and Li.)
- Subjects :
- Animals
Animals, Newborn
Antineoplastic Agents toxicity
Female
Hypoglycemic Agents pharmacology
Polycystic Ovary Syndrome chemically induced
Polycystic Ovary Syndrome metabolism
Polycystic Ovary Syndrome pathology
Rats
Rats, Wistar
Hyperinsulinism prevention & control
Insulin Resistance
Letrozole toxicity
Metabolic Syndrome prevention & control
Metformin pharmacology
Obesity prevention & control
Polycystic Ovary Syndrome drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 34484117
- Full Text :
- https://doi.org/10.3389/fendo.2021.701590